We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+32.52%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$971M
AUM Growth
+$171M
Cap. Flow
+$9.16M
Cap. Flow %
0.94%
Top 10 Hldgs %
68.82%
Holding
35
New
1
Increased
4
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$28.8M
2
CABA icon
Cabaletta Bio
CABA
+$21.7M
3
PHVS icon
Pharvaris
PHVS
+$16.3M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$6.44M
5
ANNX icon
Annexon
ANNX
+$3.56M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$23.4M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$19.8M
3
DVAX
Dynavax Technologies
DVAX
+$17.1M
4
TVRD
Tvardi Therapeutics
TVRD
+$4.86M
5
SYRE icon
Spyre Therapeutics
SYRE
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$151M 15.54%
3,577,267
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.34B
$125M 12.83%
10,473,913
+2,173,913
+26% +$28.8M
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$80.8M 8.32%
3,081,307
– –
PHVS icon
4
Pharvaris
PHVS
$2.44B
$73.7M 7.59%
4,868,784
+1,688,183
+53% +$16.3M
IRON icon
5
Disc Medicine
IRON
$2.97B
$59.2M 6.09%
1,332,548
-658,366
-33% -$23.4M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.92B
$41.5M 4.28%
2,305,558
– –
SVRA icon
7
Savara
SVRA
$1.19B
$37.1M 3.82%
11,622,598
– –
ACRS icon
8
Aclaris Therapeutics
ACRS
$869M
$35.3M 3.63%
3,400,000
– –
NTRA icon
9
Natera
NTRA
$46.4B
$34.1M 3.51%
700,197
– –
DVAX
10
DELISTED
Dynavax Technologies
DVAX
$31.2M 3.21%
2,415,000
-1,500,000
-38% -$17.1M
XFOR icon
11
X4 Pharmaceuticals
XFOR
$460M
$31M 3.19%
532,020
+125,270
+31% +$6.44M
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.18B
$28.6M 2.94%
3,000,000
– –
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$28.5M 2.94%
346,547
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$27.4M 2.82%
2,500,000
– –
CABA icon
15
Cabaletta Bio
CABA
$455M
$25.8M 2.66%
+2,000,000
New +$21.7M
ANNX icon
16
Annexon
ANNX
$886M
$20.1M 2.07%
5,701,926
+815,310
+17% +$3.56M
EQRX
17
DELISTED
EQRx, Inc. Common Stock
EQRX
$18.6M 1.92%
10,003,573
– –
NRIX icon
18
Nurix Therapeutics
NRIX
$2.65B
$18.2M 1.88%
1,822,883
– –
SLDB icon
19
Solid Biosciences
SLDB
$900M
$16.4M 1.69%
3,130,422
– –
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.5M 1.6%
1,431,058
– –
TSVT
21
DELISTED
2seventy bio
TSVT
$14.3M 1.47%
1,408,901
– –
AVIR icon
22
Atea Pharmaceuticals
AVIR
$420M
$9.3M 0.96%
2,485,638
– –
RPID icon
23
Rapid Micro Biosystems
RPID
$86.2M
$8.43M 0.87%
8,434,560
– –
NAUT icon
24
Nautilus Biotechnolgy
NAUT
$115M
$7.74M 0.8%
2,000,000
– –
XLO icon
25
Xilio Therapeutics
XLO
$60.3M
$7.35M 0.76%
200,387
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2023 Portfolio in Review

As of Q2 2023, Bain Capital Life Sciences Investors held 35 positions worth $971M, up 21% from $800M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Bain Capital Life Sciences Investors's Q2 2023 filing shows 1 new, 4 increased, 3 reduced and 3 closed positions. Its largest new stake was Cabaletta Bio: 2,000,000 shares worth $25.8M. The largest sale was Disc Medicine, an estimated $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q2 2023 buy was Cabaletta Bio: 2,000,000 shares worth $25.8M.
  • Bain Capital Life Sciences Investors added most to NewAmsterdam Pharma in Q2 2023, an estimated $28.8M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2023 reduction was Disc Medicine, cutting an estimated $23.4M.
  • Bain Capital Life Sciences Investors fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $19.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 69% of its $971M portfolio in Q2 2023.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 3 in Q2 2023.
  • Bain Capital Life Sciences Investors's portfolio value rose 21% quarter-over-quarter to $971M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2023, filed 14 Aug 2023.